Bayer said Thursday that its Xarelto blood thinner, chemically known as rivaroxaban, helped patients who had experienced Acute Coronary Syndrome and will and the drug maker will file for market authorization by the end of the year.

The Leverkusen-based firm announced the results of a Phase III ATLAS ACS TIMI 51 clinical trial plus standard therapy met its primary efficacy endpoint.

Acute coronary syndrome occurs when the heart muscle does not receive enough oxygen-rich blood. AC includes heart attacks, an unstable angina, or sudden severe chest pain that occurs when a person is at rest, according to the National Institutes of Health.

The trial found “a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction and stroke compared to standard therapy plus placebo.”

However the study found an increase of “major bleeding events not associated with Coronary Artery Bypas Graft surgery according to the TIMI-classification.”

Bayer said Thursday that the Phase III ATLAS ACS TIMI 51 clinical trial of Rivaroxaban plus standard therapy met its primary efficacy endpoint, showing a statistically significant reduction in the rate of events for the primary composite endpoint of cardiovascular death, myocardial infarction and stroke in patients with ACS, compared to standard therapy plus placebo.